摘要
非酒精性脂肪性肝病(NAFLD)的早期干预已获得大多数学者认同。保肝抗炎药物包括多烯磷脂酰胆碱、维生素E、水飞蓟素、熊去氧胆酸、甘草酸制剂和己酮可可碱等,是NAFLD综合治疗的重要组成部分。本文重点综述保肝抗炎药物的适用人群及常用药物的选用。多项临床研究提示,保肝抗炎药物可改善NAFLD患者的临床症状和血清氨基转移酶水平,但大多数保肝抗炎药物对肝脏纤维化进程的改善依据尚不足。
The early intervention of nonalcoholic fatty liver disease （NAFLD） has been admitted by most scholars. Hepatoprotectants including polyene phosphatidylcholine, vitamin E, silymarin, ursodeoxycholic acid, glycyrrhizin, pentoxifylline and so on have been considered as an important group to treat NAFLD. This review mainly describes the objects suitable for hepatoprotectants therapy and the adoption of commonly used drugs. Many clinical researches indicate that hepatoprotectants can improve the symptoms and levels of aminotransferases of NAFLD patients. However, there is no sufficient evidence to support their effects on the improvement of liver fibrosis.
出处
《世界临床药物》
CAS
2010年第9期526-529,537,共5页
World Clinical Drug
关键词
保肝药物
脂肪性肝病
非酒精性
hepatoprotectant
fatty liver disease
nonalcoholic
